Bloom Announces Early 2026 UK Launch, Expanding into Europe with New Garden Pharma as Exclusive Manufacturer
Bloom Announces Early 2026 UK Launch, Expanding into Europe with New Garden Pharma as Exclusive Manufacturer.
Share
This marks Bloom's first international market expansion, as the company continues its global growth strategy with additional EU markets in development for 2026 and beyond. UK patients will gain access to Bloom's superior formulations and proprietary hardware systems.
For more than a decade, Bloom has built its reputation on delivering terpene-rich, flavor-forward strains paired with reliable technology. The brand has an established and leading presence across leading U.S. markets including California, Illinois, Florida, Michigan, Missouri, New Jersey, New Mexico, New York, and Virginia.
'Expanding into the UK is a pivotal step towards our mission to reshape the global cannabis experience,' said Ovidiu (David) Chiorpec, Director of Business Development at Bloom. 'We've spent over a decade building a brand that patients trust in the U.S., and we're excited to introduce the UK consumer to a new level of excellence and sophistication in the vape category.'
New Garden Pharma, medical subsidiary of New Garden Group, is a trusted name in European cannabis manufacturing who combines a unique supply chain model with a proven track record in regulatory compliance and market expansion. With established infrastructure across the continent, the company will lead Bloom's UK entry — ensuring a compliant, efficient, and scalable launch across all channels.
'We're excited to welcome Bloom to the UK market,' said Alexey Brylev, CEO of New Garden Group. 'As an established operator across European medical cannabis markets, we bring the EU-GMP manufacturing expertise, local insight, and regulatory know-how needed to help global brands thrive. This partnership reflects our broader mission: to deliver world-class products to European patients and to raise the bar for quality, safety, and innovation across the continent.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Stock market today: Nasdaq eyes record close as investors shake off tariff threats, bitcoin touches latest record
US stocks rose modestly on Monday as Wall Street braced for a turbulent week, as renewed trade tensions injected uncertainty ahead of a key inflation report and the first wave of second quarter earnings. The S&P 500 (^GSPC) and Dow Jones Industrial Average (^DJI) drifted about 0.2% higher, while the tech-heavy Nasdaq Composite (^IXIC) added around 0.4%. Meanwhile, bitcoin (BTC-USD) spiked above $123,000 for the first time as investors greeted the open of Congress's "Crypto Week," but the asset dropped back near $120,000 later in the day. Stocks with crypto ties also rallied as the House of Representatives weighs three key pieces of crypto-related legislation. Earlier in the day, investors showed a diminished appetite for risk after President Trump said Saturday that the US will impose 30% tariffs on goods from the EU and Mexico from Aug. 1. The increased pressure on key US trading partners is testing the market's previous resilience in the face of escalating tariff tensions. Faith in the idea that Trump will back off from threatened hikes helped lift stocks to all-time highs last week. Officials from the EU and Mexico are pushing to continue negotiations with the US in hopes of securing a lower rate via a new deal. The hiked tariffs as they stand are seen as likely to remake global trade relations and add to existing inflationary pressures. Read more: The latest on Trump's tariffs That adds uncertainty ahead of consumer inflation data scheduled for release this week. Investors are looking to the June CPI report for signs of how earlier rounds of tariffs are impacting prices across the US economy. The reading will feed into expectations for the Fed's decision on interest rates due in just over two weeks. Meanwhile, Trump ratcheted up tensions with Russia over the war in Ukraine on Monday, threatening to impose "secondary" tariffs of up to 100% on the country. He also said the US would provide weapons to Ukraine. Earnings season kicks into swing this week, with all the major US banks due to report results starting on Tuesday. Investors are showing interest in IPO and M&A markets, while Wells Fargo (WFC) reports after being freed from a decade of stringent regulatory restrictions. June's Consumer Price Index (CPI) is expected to show prices rose at a faster clip compared to May. The report, due Tuesday at 8:30 a.m. ET, comes as investors closely monitor whether President Trump's tariffs are starting to filter through to what consumers pay, even as inflation data has so far remained more resilient than expected. According to Bloomberg data, headline CPI is expected to have increased 2.6% year over year in June, up from a 2.4% rise in May. On a monthly basis, prices are forecast to climb 0.3%, marking an acceleration from the 0.1% gain the prior month. On a "core" basis, which strips out volatile food and energy prices, the annual inflation rate for June is expected to come in at 2.9%, a slight pickup from May's 2.8%. Core prices are also projected to climb 0.3% month over month, outpacing the previous 0.1% rise seen in May. In May, falling car and apparel prices, categories seen as early indicators of tariff impacts, contributed to a cooler-than-expected core CPI reading. But economists expect those trends to reverse in June, potentially pushing core inflation higher. The report lands amid renewed trade tensions between the US and other countries. President Trump has unveiled new letters to over 20 countries outlining tariffs ranging from 20% to 50%, including a 35% duty on Canadian goods and 30% tariffs on imports from Mexico and the European Union. He has also floated sweeping 15% to 20% tariffs on most trading partners. The EU, in response, is scrambling to negotiate while preparing potential countermeasures. Read more here. The stock market continues to shake off President Trump's latest tariff threats. New letters from Trump over the weekend threatened 30% duties on goods from Mexico and the European Union. On Monday, he threatened 100% tariffs on Russia. Still, the S&P 500 (^GSPC) rose about 0.2% on Monday. Sure, perhaps part of this is the so-called TACO trade, a calling card for investors to stay invested because "Trump always chickens out" on his highest tariff threats. But Morgan Stanley chief investment officer Mike Wilson points out there's likely something more mathematical at play. The recent tariff announcements have said nothing about China, and as our Chart of the Day from Wilson shows, that's what matters to the widest array of industries. Wilson segmented various industries into different subsectors of exposure to tariffs. Seven categories, including technology and semiconductors, have "more material risk," meaning that import exposure in that group from China is more than 15% of the global total of imports. In other words, tariffs on China would hurt sectors like the tech sector more than tariffs on nearly any other country listed in Wilson's work. "The more material trade-elated risk for equity indices would be if tariff rates on China were to increase materially from here," Wilson wrote. "China is significant not only because of the number of industries with tariff cost exposure, but also because of the market cap weighting of those industries, in aggregate." Yahoo Finance's Brooke DiPalma reports: Read more here. Meta (META) stock gained 1% after CEO Mark Zuckerberg announced on Monday that the company plans to build several data centers in the US. "Meta Superintelligence Labs will have industry-leading levels of compute and by far the greatest compute per researcher," Zuckerberg wrote in a post on Threads. The news followed several high-profile AI hires at Meta as the tech company looks to spend billions to advance its AI efforts and break free of its dependence on third-party companies. Yahoo Finance's Daniel Howley reports: Read more here. Procter & Gamble (PG) stock slipped about 2% on Monday after Evercore ISI analysts downgraded shares to In Line from Outperform, citing retail channel shifts and macro uncertainty. The analysts noted that P&G's sales growth could become capped as more consumers purchase household and personal care (HPC) items online with Amazon (AMZN) instead of at retailers like Walmart (WMT) and Costco (COST). "Our concern ... increasingly lies in adverse shifts in retail channels that challenge Procter's growth potential," the analysts wrote. "In the U.S., Amazon now accounts for 50% of all HPC growth, which creates a 2-point growth gap or one point globally relative to Procter's core retailers, mainly Walmart and Costco, where the firm remains competitively advantaged given scale and product superiority. A parallel shift to pure online in China compounds macro pressures and could delay a turnaround, in our view." Procter & Gamble's market share at Amazon is about one-third its share at Costco and Walmart, the analysts noted. They cut their price target on P&G stock to $170 from $190. Yahoo Finance's Jennifer Schonberger reports: Read more here. US stocks were little changed after President Trump floated secondary tariffs of up to 100% on Russia if the country does not make progress toward ending its war with Ukraine in 50 days. The S&P 500 (^GSPC) and Dow Jones Industrial Average (^DJI) were roughly flat Monday afternoon, while the tech-heavy Nasdaq Composite (^IXIC) added about 0.2%. Per the FT: The tariffs Trump threatened would theoretically apply to the imports of countries that trade with Russia. Direct US trade with Russia has plummeted amid the war, but Russia still trades with many countries in Europe and Asia — most notably China. Yahoo Finance's Pras Subramanian reports: Read more here. Another Wall Street firm no longer sees the S&P 500 declining to finish the year. In a note to clients on Sunday, RBC Capital Markets boosted its year-end S&P 500 target to 6,250 from a prior target of 5,730. As RBC Capital Markets' Lori Calvasina noted, the adjustment comes amid the market's more than 25% bounce back from the April lows and essentially moves their target back to where it sat in mid-March before the bulk of the tariff turmoil began. "We feel neutral on the outlook for stocks in the 2nd half of 2025, and are mindful that our new price target is essentially in line with recent levels," Calvasina wrote. "We expect choppy conditions in the back half of the year, and swings in both directions." Calvasina noted that it's likely still "too early to stop worrying about tariff impacts" on corporate earnings and also highlighted a slowdown in recent momentum as reasons she remains cautious that the next major move for the benchmark index is higher. While Calvasina is at least the ninth strategist tracked by Yahoo Finance to recently raise their S&P 500 target from their April downward revision, she's also part of a growing list of those who aren't pounding the table for the rally to continue. Yardeni Research president Ed Yardeni, who maintains a 6,500 year-end target for the S&P 500, wrote in a note to clients on Sunday that the recent V-shape recovery in stocks could soon look more like a "square-root shaped pattern" where the rapid rise higher stalls out. Apple (AAPL) stock fell 1.2% in early trading on Monday as the iPhone maker faces pressure to shake up its artificial intelligence efforts and potentially acquire an established AI startup, such as Perplexity AI ( Bloomberg reports: Read more here. US stocks pulled back slightly on Monday as Wall Street braced for a turbulent week, with renewed trade tensions injecting uncertainty ahead of a key inflation report and the first wave of second-quarter earnings. The S&P 500 (^GSPC) was off about 0.1%, while the tech-heavy Nasdaq Composite (^IXIC) was roughly flat. The Dow Jones Industrial Average (^DJI) fell about 0.2%. Crypto stocks added to this year's gains on Monday as bitcoin (BTC-USD) surpassed $120,000 for the first time. The rally in crypto highlighted optimism in the sector as House lawmakers kicked off "Crypto Week," which is expected to result in new crypto-friendly stablecoin legislation. Coinbase (COIN), the largest crypto exchange, rose 1.6%, while Robinhood (HOOD) gained nearly 3%. Stablecoin issuer Circle (CRCL) added 0.5%. Strategy (MSTR) was up 2.8%. The Michael Saylor-led firm is one of the largest corporate holders of bitcoin through its bitcoin treasury. Bitcoin was trading just below $121,000 as of 9 a.m. ET. Here's a look at stocks moving ahead of the opening bell: Nio (NIO): US-listed shares of Nio jumped 5% in premarket trading after the Chinese EV maker unveiled its line of ONVO L90 SUVs, which will be launched at the end of July. Early pre-sales boosted optimism about the competitiveness of the seven-seater vehicle. Nebius Group (NBIS): Nebius stock soared more than 7% after Goldman Sachs initiated coverage with a Buy rating, citing the company's role in providing AI infrastructure. Tesla (TSLA): Tesla stock rose 1.3% ahead of a shareholder vote to determine whether to invest in CEO Elon Musk's xAI startup. Musk announced the vote after SpaceX reportedly agreed to invest $2 billion in xAI. Lionsgate (LION): Lionsgate shares surged 11% premarket on reports that Legendary Entertainment was considering taking over the film studio. Check out more trending tickers here. Wall Street's giant lenders are getting set to report their second quarter results this week, kicking off earnings season in earnest. What a difference a quarter makes for the mood surrounding the US's largest banks, Yahoo Finance's David Hollerith reports: Read more here. Kenvue (KVUE) stock rose 4% in premarket trading after the company said CEO and board member Thibaut Mongon stepped down as part of a strategic review. The Tylenol maker, which spun off from Johnson & Johnson (JNJ) in 2023, named company director Kirk Perry as interim chief executive, per Reuters. "The Board's strategic review is underway, and we are considering a broad range of potential alternatives, including ways to simplify the company's portfolio and how it operates," board chair Larry Merlo said. Read more here. Stocks are on the back foot before the bell, but are still trading near record highs heading into a busy week of economic data and quarterly earnings reports. Yahoo Finance's Myles Udland lays out the highlights in what's coming this week: Read more here. Yahoo Finance UK's Lucy Harley-McKeown reports: The FTSE 100 (^FTSE) ticked higher and European stocks dropped on Monday morning, as traders digest the latest round of tariff threats by US President Donald Trump. The US and UK have already struck a partial trade deal, meaning tariff threats have less impact on the FTSE. Read more here. Reuters reports: Read more here. Bloomberg reports: Read more here. Gold (GC=F) rises with tariff threats from Trump driving investors toward the safe-haven commodity. Bloomberg reports: Read more here. June's Consumer Price Index (CPI) is expected to show prices rose at a faster clip compared to May. The report, due Tuesday at 8:30 a.m. ET, comes as investors closely monitor whether President Trump's tariffs are starting to filter through to what consumers pay, even as inflation data has so far remained more resilient than expected. According to Bloomberg data, headline CPI is expected to have increased 2.6% year over year in June, up from a 2.4% rise in May. On a monthly basis, prices are forecast to climb 0.3%, marking an acceleration from the 0.1% gain the prior month. On a "core" basis, which strips out volatile food and energy prices, the annual inflation rate for June is expected to come in at 2.9%, a slight pickup from May's 2.8%. Core prices are also projected to climb 0.3% month over month, outpacing the previous 0.1% rise seen in May. In May, falling car and apparel prices, categories seen as early indicators of tariff impacts, contributed to a cooler-than-expected core CPI reading. But economists expect those trends to reverse in June, potentially pushing core inflation higher. The report lands amid renewed trade tensions between the US and other countries. President Trump has unveiled new letters to over 20 countries outlining tariffs ranging from 20% to 50%, including a 35% duty on Canadian goods and 30% tariffs on imports from Mexico and the European Union. He has also floated sweeping 15% to 20% tariffs on most trading partners. The EU, in response, is scrambling to negotiate while preparing potential countermeasures. Read more here. The stock market continues to shake off President Trump's latest tariff threats. New letters from Trump over the weekend threatened 30% duties on goods from Mexico and the European Union. On Monday, he threatened 100% tariffs on Russia. Still, the S&P 500 (^GSPC) rose about 0.2% on Monday. Sure, perhaps part of this is the so-called TACO trade, a calling card for investors to stay invested because "Trump always chickens out" on his highest tariff threats. But Morgan Stanley chief investment officer Mike Wilson points out there's likely something more mathematical at play. The recent tariff announcements have said nothing about China, and as our Chart of the Day from Wilson shows, that's what matters to the widest array of industries. Wilson segmented various industries into different subsectors of exposure to tariffs. Seven categories, including technology and semiconductors, have "more material risk," meaning that import exposure in that group from China is more than 15% of the global total of imports. In other words, tariffs on China would hurt sectors like the tech sector more than tariffs on nearly any other country listed in Wilson's work. "The more material trade-elated risk for equity indices would be if tariff rates on China were to increase materially from here," Wilson wrote. "China is significant not only because of the number of industries with tariff cost exposure, but also because of the market cap weighting of those industries, in aggregate." Yahoo Finance's Brooke DiPalma reports: Read more here. Meta (META) stock gained 1% after CEO Mark Zuckerberg announced on Monday that the company plans to build several data centers in the US. "Meta Superintelligence Labs will have industry-leading levels of compute and by far the greatest compute per researcher," Zuckerberg wrote in a post on Threads. The news followed several high-profile AI hires at Meta as the tech company looks to spend billions to advance its AI efforts and break free of its dependence on third-party companies. Yahoo Finance's Daniel Howley reports: Read more here. Procter & Gamble (PG) stock slipped about 2% on Monday after Evercore ISI analysts downgraded shares to In Line from Outperform, citing retail channel shifts and macro uncertainty. The analysts noted that P&G's sales growth could become capped as more consumers purchase household and personal care (HPC) items online with Amazon (AMZN) instead of at retailers like Walmart (WMT) and Costco (COST). "Our concern ... increasingly lies in adverse shifts in retail channels that challenge Procter's growth potential," the analysts wrote. "In the U.S., Amazon now accounts for 50% of all HPC growth, which creates a 2-point growth gap or one point globally relative to Procter's core retailers, mainly Walmart and Costco, where the firm remains competitively advantaged given scale and product superiority. A parallel shift to pure online in China compounds macro pressures and could delay a turnaround, in our view." Procter & Gamble's market share at Amazon is about one-third its share at Costco and Walmart, the analysts noted. They cut their price target on P&G stock to $170 from $190. Yahoo Finance's Jennifer Schonberger reports: Read more here. US stocks were little changed after President Trump floated secondary tariffs of up to 100% on Russia if the country does not make progress toward ending its war with Ukraine in 50 days. The S&P 500 (^GSPC) and Dow Jones Industrial Average (^DJI) were roughly flat Monday afternoon, while the tech-heavy Nasdaq Composite (^IXIC) added about 0.2%. Per the FT: The tariffs Trump threatened would theoretically apply to the imports of countries that trade with Russia. Direct US trade with Russia has plummeted amid the war, but Russia still trades with many countries in Europe and Asia — most notably China. Yahoo Finance's Pras Subramanian reports: Read more here. Another Wall Street firm no longer sees the S&P 500 declining to finish the year. In a note to clients on Sunday, RBC Capital Markets boosted its year-end S&P 500 target to 6,250 from a prior target of 5,730. As RBC Capital Markets' Lori Calvasina noted, the adjustment comes amid the market's more than 25% bounce back from the April lows and essentially moves their target back to where it sat in mid-March before the bulk of the tariff turmoil began. "We feel neutral on the outlook for stocks in the 2nd half of 2025, and are mindful that our new price target is essentially in line with recent levels," Calvasina wrote. "We expect choppy conditions in the back half of the year, and swings in both directions." Calvasina noted that it's likely still "too early to stop worrying about tariff impacts" on corporate earnings and also highlighted a slowdown in recent momentum as reasons she remains cautious that the next major move for the benchmark index is higher. While Calvasina is at least the ninth strategist tracked by Yahoo Finance to recently raise their S&P 500 target from their April downward revision, she's also part of a growing list of those who aren't pounding the table for the rally to continue. Yardeni Research president Ed Yardeni, who maintains a 6,500 year-end target for the S&P 500, wrote in a note to clients on Sunday that the recent V-shape recovery in stocks could soon look more like a "square-root shaped pattern" where the rapid rise higher stalls out. Apple (AAPL) stock fell 1.2% in early trading on Monday as the iPhone maker faces pressure to shake up its artificial intelligence efforts and potentially acquire an established AI startup, such as Perplexity AI ( Bloomberg reports: Read more here. US stocks pulled back slightly on Monday as Wall Street braced for a turbulent week, with renewed trade tensions injecting uncertainty ahead of a key inflation report and the first wave of second-quarter earnings. The S&P 500 (^GSPC) was off about 0.1%, while the tech-heavy Nasdaq Composite (^IXIC) was roughly flat. The Dow Jones Industrial Average (^DJI) fell about 0.2%. Crypto stocks added to this year's gains on Monday as bitcoin (BTC-USD) surpassed $120,000 for the first time. The rally in crypto highlighted optimism in the sector as House lawmakers kicked off "Crypto Week," which is expected to result in new crypto-friendly stablecoin legislation. Coinbase (COIN), the largest crypto exchange, rose 1.6%, while Robinhood (HOOD) gained nearly 3%. Stablecoin issuer Circle (CRCL) added 0.5%. Strategy (MSTR) was up 2.8%. The Michael Saylor-led firm is one of the largest corporate holders of bitcoin through its bitcoin treasury. Bitcoin was trading just below $121,000 as of 9 a.m. ET. Here's a look at stocks moving ahead of the opening bell: Nio (NIO): US-listed shares of Nio jumped 5% in premarket trading after the Chinese EV maker unveiled its line of ONVO L90 SUVs, which will be launched at the end of July. Early pre-sales boosted optimism about the competitiveness of the seven-seater vehicle. Nebius Group (NBIS): Nebius stock soared more than 7% after Goldman Sachs initiated coverage with a Buy rating, citing the company's role in providing AI infrastructure. Tesla (TSLA): Tesla stock rose 1.3% ahead of a shareholder vote to determine whether to invest in CEO Elon Musk's xAI startup. Musk announced the vote after SpaceX reportedly agreed to invest $2 billion in xAI. Lionsgate (LION): Lionsgate shares surged 11% premarket on reports that Legendary Entertainment was considering taking over the film studio. Check out more trending tickers here. Wall Street's giant lenders are getting set to report their second quarter results this week, kicking off earnings season in earnest. What a difference a quarter makes for the mood surrounding the US's largest banks, Yahoo Finance's David Hollerith reports: Read more here. Kenvue (KVUE) stock rose 4% in premarket trading after the company said CEO and board member Thibaut Mongon stepped down as part of a strategic review. The Tylenol maker, which spun off from Johnson & Johnson (JNJ) in 2023, named company director Kirk Perry as interim chief executive, per Reuters. "The Board's strategic review is underway, and we are considering a broad range of potential alternatives, including ways to simplify the company's portfolio and how it operates," board chair Larry Merlo said. Read more here. Stocks are on the back foot before the bell, but are still trading near record highs heading into a busy week of economic data and quarterly earnings reports. Yahoo Finance's Myles Udland lays out the highlights in what's coming this week: Read more here. Yahoo Finance UK's Lucy Harley-McKeown reports: The FTSE 100 (^FTSE) ticked higher and European stocks dropped on Monday morning, as traders digest the latest round of tariff threats by US President Donald Trump. The US and UK have already struck a partial trade deal, meaning tariff threats have less impact on the FTSE. Read more here. Reuters reports: Read more here. Bloomberg reports: Read more here. Gold (GC=F) rises with tariff threats from Trump driving investors toward the safe-haven commodity. Bloomberg reports: Read more here. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
31 minutes ago
Japan doesn't plan on responding to Trump tariff threats with countermeasures, government official says
TOKYO -- While the European Union has vowed to impose countermeasures if the Trump administration moves forward with its planned 30% tariffs on all EU exports to the U.S., another key strategic ally, Japan, is taking a different approach. Unlike the European Union, the Japanese government has made no indication it plans to impose any kind of reciprocal tariff on the U.S., even if the U.S. does move forward with its planned 25% tariffs on all Japanese exports. "We have no intention to change" the Japan-U.S. ally relationship, a Japanese government official told ABC News. "We will cooperate with the United States to make a win-win situation." The potential U.S. tariffs on Japanese exports only increased by 1% in the Trump administration's July letter to the Japanese government, moving from 24% to 25% from Trump's initial proposal earlier this spring. Japan has already been impacted by the 25% tariff on the overall automobile industry, as it exports cars to the U.S. from its well-known brands including Honda, Toyota, Mitsubishi, Subaru and Mazda. "That is why we continue to discuss with the U.S. administration at the minister level, of course," the official said. "We don't change our position. We explain and request it to the discussion of the minister." Japan has attempted to remain calm since President Donald Trump first announced potential tariffs on all Japanese exports this spring, sticking with a strategy of steady diplomacy, a promise to invest further in the U.S. and patience. Japanese government officials have met with their U.S. counterparts seven times since Japanese Prime Minister Shigeru Ishiba's initial meeting with Trump at the White House in February, the Japanese government official said. Trump and Ishiba also met on the sidelines of the G7 summit in Canada in June before Trump cut his trip short. Ishiba was the second world leader to visit Trump at the White House after he took office in January. Hideo Kumano, Japanese chief economist at Dai-ichi Life Research Institute, warned if the U.S. tariffs are imposed on Japanese goods, Japan will likely see a recession. "It's inevitable to see some kind of damage," Kumano told ABC News. "There is a possibility that we will fall into recession." But Kumano said he doesn't think Japan should retaliate like some other countries have to Trump's tariff threats. "Trump is emotional, and countries like India or Brazil, they reacted in the same manner, and they also wanted to punish such a policy and impose high tariffs in response," Kumano said. "Europe is insinuating something like that, but I don't think Japan should do the same." Instead, Kumano believes Japan should "smile superficially" and then "behind the scenes," prepare for the potential impacts of the coming tariffs. "Behind the scenes, Japan or Japanese companies should react to potential impact of the tariffs and control or manage the transactions with the U.S.," Kumano said.
Yahoo
32 minutes ago
- Yahoo
Legal Steroid Alternatives for Muscle Growth 2025: CrazyBulk Introduces Effective Legal Steroid Alternatives For Bulking, Cutting, Fat Loss, and Strength in USA
CrazyBulkNew York City, NY, July 11, 2025 (GLOBE NEWSWIRE) -- CrazyBulk, a leading provider of legal steroid alternatives, is excited to announce its expanded line of top-rated, natural supplements designed to help athletes and fitness enthusiasts build muscle, enhance strength, and lose fat. These cutting-edge products are formulated to provide safe, effective results, mimicking the effects of anabolic steroids without the associated side effects and legal risks. In a world where the pursuit of peak performance and aesthetic goals often leads people to seek illegal and dangerous steroid options, CrazyBulk offers a powerful and legal alternative that is both safe and effective. By using scientifically-backed, natural ingredients, CrazyBulk's Legal steroid alternatives for muscle growth can help individuals achieve their fitness goals while maintaining their overall health and well-being. The Science Behind CrazyBulk's Legal Steroid Alternatives For Muscle Growth: CrazyBulk's products are developed using natural ingredients that have been proven to work effectively. Key ingredients such as beta-hydroxy-beta-methylbutyrate (HMB), D-Aspartic Acid, and Tribulus Terrestris have been studied for their role in enhancing muscle retention, boosting testosterone, and supporting fat loss. These ingredients mimic the effects of anabolic steroids while ensuring the safety of the user. Beta-Hydroxy-Beta-Methylbutyrate (HMB): Known for its muscle-preserving properties, HMB helps prevent muscle loss, especially during cutting phases. D-Aspartic Acid: A powerful amino acid that helps increase testosterone production, promoting muscle growth and strength. Tribulus Terrestris: A plant extract used to naturally enhance libido and support testosterone levels, improving overall fitness performance. Why Choose CrazyBulk's Legal Steroid Alternatives? No Harmful Side Effects: These products are designed to deliver the benefits of anabolic steroids without the negative health implications. Natural, Effective Ingredients: Each product features ingredients like beta-hydroxy-beta-methylbutyrate (HMB), D-Aspartic Acid, and Tribulus Terrestris, which are widely recognized for their ability to support muscle building, fat loss, and overall physical performance. Designed for Real Results: CrazyBulk's supplements are backed by real-world results from customers who have achieved their fitness goals without compromising their health. How to Choose Legal Steroid Alternatives For Muscle Growth? Unlike traditional anabolic steroids, which can cause serious health issues such as liver damage, increased risk of heart disease, hormonal imbalances, and behavioral changes, CrazyBulk's legal steroid alternatives are specifically designed to help individuals gain muscle, burn fat, and improve strength safely. CrazyBulk supplements are manufactured in FDA-inspected, GMP-certified facilities to ensure the highest quality and safety. Key Features of CrazyBulk's Legal Steroid Alternatives: Legal and Safe Alternatives: No need for dangerous anabolic steroids or risky injections. CrazyBulk's supplements are made with natural ingredients that mimic the effects of steroids without harmful side effects. Improved Performance: These supplements are scientifically formulated to enhance strength, stamina, and endurance, helping users push through their workouts and break through fitness plateaus. Rapid Muscle Growth: By increasing nitrogen retention and protein synthesis, CrazyBulk products stimulate rapid muscle gains without the water retention commonly associated with traditional steroids. Fat Loss: Many of these products also promote fat-burning, allowing users to achieve a leaner physique while preserving muscle mass. Natural Ingredients: Every product is carefully crafted using natural, research-backed ingredients, ensuring that users can enhance their performance and physique without compromising their health. Clinically Researched: While individual results can vary, the key ingredients used in CrazyBulk products have been shown to support muscle growth, fat loss, and improved physical performance. Product Range and Highlights: D-Bal (Alternative to Dianabol): Supports rapid muscle growth and strength. Enhances nitrogen retention, which aids muscle recovery and growth. Helps users experience maximum strength during intense training sessions. 2. Testo-Max (Alternative to Sustanon 250): Naturally increases testosterone production, which boosts strength and muscle mass. Increases energy and stamina for better performance during workouts. Supports faster muscle recovery and enhanced overall performance. 3. Tren-Max (Alternative to Trenbolone): Helps burn fat while maintaining lean muscle mass. Perfect for cutting cycles, helping users achieve a shredded physique. Increases energy levels and endurance during workouts. 4. Anvarol (Alternative to Anavar): Supports fat loss while preserving lean muscle tissue. Ideal for cutting cycles and increasing vascularity. Boosts strength and endurance, allowing for more intense training sessions. 5. Clenbutrol (Alternative to Clenbuterol): Promotes fat burning by increasing metabolism and energy levels. Enhances performance and improves aerobic capacity. Helps users maintain a lean physique without losing muscle mass. Each of these products is crafted with a unique blend of ingredients that have been carefully selected for their ability to naturally support muscle growth, fat loss, and strength enhancement. Whether you're looking to bulk up, cut fat, or improve your performance, CrazyBulk's offer a Best legal steroid alternatives safe and effective Steroid Alternatives For Muscle Growth by CrazyBulk Safe and Effective Ingredients: CrazyBulk supplements contain ingredients such as beta-hydroxy-beta-methylbutyrate (HMB), D-Aspartic Acid, Tribulus Terrestris, and many more, all known for their ability to support muscle growth, fat loss, and overall physical performance. These ingredients are backed by clinical studies and have been shown to produce results similar to those of traditional anabolic steroids, without the harmful side effects. Beta-Hydroxy-Beta-Methylbutyrate (HMB), for example, is widely recognized for its ability to promote lean muscle retention and fat loss, making it an excellent choice for those looking to maintain muscle mass while cutting body fat. Safety and Efficacy: Each CrazyBulk product is manufactured in FDA-inspected, GMP-certified facilities, ensuring the highest standards of quality and safety. Unlike synthetic steroids, which carry potential risks like liver damage, cardiovascular issues, and hormonal imbalances, CrazyBulk's alternatives offer a non-toxic, non-harmful approach to muscle building and fat loss. Unlike anabolic steroids, CrazyBulk products are designed with user safety in mind. The ingredients are non-toxic, and clinical studies have shown that they are just as effective as anabolic steroids in promoting muscle growth, fat loss, and strength, without the negative health consequences. Furthermore, CrazyBulk supplements do not require injections, and they are completely legal to purchase and use without a prescription. This makes them an ideal option for individuals who are serious about improving their performance without compromising their health or breaking the law. What Sets CrazyBulk Legal Steroid Alternatives Apart? Proven Results: CrazyBulk products are backed by customer testimonials, real-world results, and clinical research. 100% Natural Ingredients: CrazyBulk's supplements are made with natural, safe ingredients that are free from harmful chemicals and steroids. Customer Satisfaction: CrazyBulk is committed to customer satisfaction and offers a 100% money-back guarantee if customers are not satisfied with their products. Expert Formulations: The company's supplements are formulated by fitness experts and professionals, ensuring that each product delivers maximum effectiveness. About CrazyBulk Legal Steroid Alternatives For Muscle Growth: CrazyBulk is a leading supplement brand specializing in Best legal steroid alternatives designed to help athletes and fitness enthusiasts reach their muscle-building, fat-burning, and strength-enhancing goals. With a focus on natural ingredients and customer safety, CrazyBulk offers a wide range of products formulated to maximize workout performance without the risks associated with anabolic steroids. With a commitment to quality and excellence, CrazyBulk continues to be the trusted choice for individuals seeking to improve their fitness and achieve their physique goals. For more information about CrazyBulk's products, ingredients, and to make a purchase, please visit Company Name and Location Launch Date & Availability CrazyBulk's new line of legal steroid alternatives for muscle growth is available now, starting from April 29, 2025. These products can be purchased directly through the official CrazyBulk website at https::// With a wide range of options designed for muscle growth, fat loss, and strength enhancement, these science-backed, natural supplements are ready to help athletes and fitness enthusiasts achieve their goals safely and effectively. Scientific Data and Studies i CrazyBulk's legal steroid alternatives are formulated using scientifically proven ingredients supported by clinical studies. Key components like D-Aspartic Acid have been shown to increase testosterone production, improving muscle growth and strength. Beta-Hydroxy-Beta-Methylbutyrate (HMB) helps prevent muscle breakdown and supports fat loss, as demonstrated in numerous studies on muscle preservation during cutting cycles. Tribulus Terrestris has been linked to improved strength and enhanced performance. All ingredients are selected based on peer-reviewed research, ensuring that CrazyBulk products deliver the desired results without the adverse side effects of traditional anabolic steroids. Health & Safety Benefits of CrazyBulk's Legal Steroid Alternatives Safe and Natural: Made from 100% natural ingredients, offering a safer alternative to traditional anabolic steroids. No Harmful Side Effects: Unlike anabolic steroids, CrazyBulk's products do not cause liver damage, hormonal imbalances, or cardiovascular issues. Muscle Growth: Ingredients like D-Aspartic Acid boost testosterone production, supporting enhanced muscle growth and strength. Fat Loss & Muscle Retention: HMB helps preserve lean muscle while promoting fat loss, ideal for cutting cycles. Improved Recovery: Natural compounds accelerate recovery, reducing muscle soreness and allowing for more intense workouts. Energy & Performance Boost: Tribulus Terrestris and other ingredients increase stamina, endurance, and workout performance. Manufactured Safely: Produced in FDA-inspected, GMP-certified facilities to ensure top-quality standards and safety. Effective & Legal: Achieve your fitness goals legally and safely, with the same benefits of anabolic steroids, without the risks. Market Disruption by CrazyBulk's Legal Steroid Alternatives Safer Alternative to Traditional Steroids: CrazyBulk disrupts the market by providing a legal and safe alternative to anabolic steroids, which have well-known health risks. Natural Ingredients with Proven Effectiveness: By focusing on natural, research-backed ingredients, CrazyBulk challenges the reliance on synthetic substances and harmful chemicals in bodybuilding supplements. Convenient & Easy to Use: Unlike injectable steroids, CrazyBulk's supplements come in easy-to-take pill or capsule form, offering a hassle-free user experience. Cost-Effective: With no need for expensive medical treatments or prescriptions associated with steroids, CrazyBulk's products offer an affordable option for muscle growth and fat loss. Legality and Safety: CrazyBulk products are legally available and free from the legal and health concerns tied to anabolic steroid use, attracting a broader customer base. High-Quality Standards: Manufactured in FDA-inspected, GMP-certified facilities, CrazyBulk sets new industry standards for quality and safety. Consumer Benefits of CrazyBulk's Legal Steroid Alternatives Safe and Effective: Offers the muscle-building benefits of anabolic steroids without harmful side effects. Natural Ingredients: Made with scientifically proven, natural ingredients that enhance muscle growth, fat loss, and strength. Convenient Use: Available in easy-to-take pills or capsules, eliminating the need for injections. Boosts Performance: Increases strength, stamina, and endurance, leading to more effective workouts. Supports Fat Loss: Promotes fat burning while preserving lean muscle mass, ideal for cutting cycles. No Legal Issues: Fully legal and safe to use, without the risks of traditional steroids. High Quality: Manufactured in FDA-inspected, GMP-certified facilities to ensure product safety and efficacy. Distribution Channels Official CrazyBulk's Legal Steroid Alternatives Website Direct-to-Consumer Sales: Ensuring authenticity, best pricing, and support. Global Shipping: CrazyBulk's delivers to the USA, UK, Canada, Australia, and 130+ countries. No Third-Party Retailers: Only available online from the brand for guaranteed quality. Website URL & Contact Person Details Website: https::// Contact Email: support@ Customer Service: 24/7 live chat and email support available Safety Certifications and Testing FDA-Registered Facilities GMP-Certified Manufacturing ISO Quality Standards Third-Party Lab Testing for Purity and Potency Visit the Official CrazyBulk's website to learn more, read real reviews, and discover the science of Legal Steroid Alternatives Manufactured under the Technical Guidance of: Project name: Crazybulk Official Website: https::// 244 Madison Avenue, New York City, NY 10016-2817 Postal code: NY 10016-2817 Media Contact: Full Name - Neil Bowers email: support@ +1 888-708-6394 Contact Us for Advertising: Info@ Attachment CrazyBulk CONTACT: Project name: Crazybulk Official Website: https::// 244 Madison Avenue, New York City, NY 10016-2817 Postal code: NY 10016-2817 Media Contact: Full Name - Neil Bowers email: support@ +1 888-708-6394 Contact Us for Advertising: Info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
